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THE ORIGINAL OR LANDMARK STUDIES                       
Initially the landmark statin trials proved the benefi t of using HMG CoA 
reductase inhibitors or “statins” in the hypercholesterolemic patient 
with heart disease. The Scandinavian Simvastatin Survival Study (4S) 
was such a secondary prevention study in which patients with angina or 
prior myocardial infarction with elevated cholesterol were randomized 
to receive either simvastatin or placebo and followed over a median of 
5.4 years. There was a signifi cant reduction in MACE rates as well as a 
reduction in the need for further coronary revascularization.(1) 
Following on the success of this secondary prevention trial, major 
primary prevention trials which examined the role of statins in 
hypercholesterolemic men without a prior history of myocardial 
infarction were reported. The West of Scotland Primary Prevention 
Study (WOSCOPS) demonstrated a 31% reduction in non-fatal 
myocardial infarction or coronary deaths, a 37% reduction in 
revascularization procedures and overall a 32% reduction in 
cardiovascular mortality.(2)
The Long Term Intervention with Pravastatin in Ischemic Disease 
(LIPID) study emphasized the importance of statins in secondary 
prevention by reducing mortality across a wide range of serum 
cholesterol levels (4-7 mmol/L) in long-term (mean 6.1 years) treatment. 
The benefi t was mostly shown in patients with high cholesterol levels 
at baseline.(3)
The Cholesterol and Recurrent Events (CARE) study published 
reductions in coronary events by 24% in patients with prior history of 
cardiovascular disease but with average cholesterol levels (5.4+/- 
0.4mmol/l).(4)
Most of these trials failed to show reductions in non-cardiovascular 
events.
One of the largest statin trials to date, the Heart Protection Study 
(HPS) demonstrated signifi cant reductions in MACE, strokes and in 
revascularization procedures regardless of initial LDL levels.(5) Total 
mortality was reduced signifi cantly (RR 0.87, 95%CI 0.81-0.91, 
p=0.0003). The benefi t was clearly seen in the elderly, in a high risk 
population, in female patients, diabetics and in patients with non-cardiac 
atheromatous disease. In fact there was a proportional reduction in 
adverse events in all categories of lipid levels, even those with low LDL 
levels.
Reductions in MACE with statin use as primary prevention in an average 
risk population with normal total cholesterol (5.7+/- 0.54 mmol/L) but 
with low HDL (<0.16mmol/L for men and <1.22mmol/L for women) 
was also demonstrated in the Air Force/Texas Coronary Atherosclerosis 
Prevention Study (AFCAPS/TEXCAPS).(6)
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The explosion of medical knowledge and 
the importance and real reductions in adverse cardio-
vascular events with improving medical therapy has seen a 
surge in large trials investigating the use of HMG-CoA 
reductase inhibitors (statins) in the treatment of patients 
with cardiovascular disease since the 1990s. The established 
pathological role of low density lipoprotein (LDL) 
cholesterol and the effi cacy of the lipid lowering properties 
of statins have ushered in an effective means of managing 
and preventing major adverse cardiovascular events 
(MACE). The purpose of this article is to review the evidence 
to date illustrating the benefi ts of statin therapy and 
highlight some of the key features of the landmark trials in 
order to gain more insight in their use in the acute coronary 
syndromes. SAHeart 2008; 5:66-69
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TREATMENT IMMEDIATELY AFTER ACUTE                    
CORONARY SYNDROMES
As statins gained popularity, further research began to  explore their 
potential pleiotrophic effects. Statins can modify endothelial function, 
stabilize plaques, reduce infl ammation and prevent thrombus formation. 
It seemed logical that the next step would be to use them early in the 
setting of the acute coronary syndromes.
In the Myocardial Ischemia Reduction with Aggressive Cholesterol 
Lowering (MIRACL) trial, high dose (80mg daily) atorvastatin used early 
(within 24-96 hours) in non-Q wave myocardial infarction and unstable 
angina demonstrated a mean reduction in total cholesterol of 34% and 
signifi cant reduction in recurrent unstable angina (26%) but no signifi cant 
change in death, non-fatal myocardial infarction or cardiac arrest at 16 
weeks follow-up.(7) This was a randomized, placebo-controlled trial and 
demonstrated a reduction in composite cardiovascular events by 16% 
(p=0.048) over the ensuing 4 months. Perhaps even more striking was 
the 50% reduction in stroke achieved in this study.
The Atorvastatin Versus Revascularization Treatment (AVERT) study 
compared aggressive atorvastatin therapy to coronary angioplasty. 
Although risk reduction was not signifi cant after adjustment for interim 
analysis, the time to reach an ischemic event was signifi cantly longer in 
the atorvastatin group (RR 0.64, 0.33-0.95, p=0.03).(8)
MORE AGGRESSIVE TREATMENT                                        
Since higher doses of statins are able to lower lipid levels more 
signifi cantly, especially in the acute setting, questions arose as to whether 
high dose statin therapy, particularly with the use of the more potent 
statins, may lower event rates more than standard dose therapy.
In the Pravastatin or Atorvastatin Evaluation and Infection Therapy-
Thrombolysis in Myocardial Infarction 22 (PROVE-IT) trial, patients 
were randomized to standard therapy or intensive therapy 10 days 
after an episode of acute coronary syndrome.(9)  The primary end-point 
was the composite of death, myocardial infarction, hospitalized unstable 
angina, revascularization and stroke. At the end of two years, the 
primary end point rate was 26.3% with standard therapy and 22.4% 
with intensive therapy. Progressively lower risk with progressively lower 
achieved LDL-cholesterol levels was achieved even in those patients 
with relatively low initial LDL-cholesterol levels.
A similar  reduction in the composite primary end-point was observed 
in the A to Z trial.(10) This occurred more signifi cantly when early 
intensive therapy where high dose statin (simvastatin 80 mg daily)  was 
initiated within 5 days of presenting with acute coronary syndrome 
than with delayed conservative therapy where lower dose statin was 
given 4 months after presentation. 
In the Treating to New Targets (TNT) study, patients with stable 
coronary artery disease who achieved LDL levels after an 8-week run-
in period on low dose atorvastatin were randomized to either 10mg or 
80mg atorvastatin daily. The mean LDL-cholesterol levels obtained 
were 2.6 mmol/l on the 10mg dose compared to 2.0 mmol/l on the 
80mg dose of atorvastatin. A 22% reduction in cardiac events following 
a mean follow-up period of 5 years was seen with intensive therapy but 
overall mortality was not signifi cantly different.(11)
In the Reversal of Atherosclerosis with Aggressive Lipid Lowering 
(REVERSAL), luminal stenosis measured on intravascular ultrasound 
was shown to be signifi cantly increased after 18 months in patients 30-
75 years old with moderate lipid therapy compared with intensive 
therapy.(12)
In the Incremental Decrease in Endpoints through Aggressive Lipid 
Lowering (IDEAL) study,  patients were randomized to either 20mg or 
80mg of atorvastatin daily.(13) Patients selected were those with a prior 
history of myocardial infarction and most were therefore already on a 
statin. The primary endpoint of the trial was time to fi rst occurrence of 
coronary death, myocardial infarction or resuscitated cardiac arrest 
over a 5-year period. An 11% signifi cant reduction in the primary 
endpoint occurred with intensive therapy.
A meta-analysis of the A to Z, IDEAL, PROVE-IT and TNT studies 
compared intensive versus moderate statin therapy.(14) This showed a 
16% (p<0.0001) reduction in coronary death or myocardial infarction, 
and an 18% reduction in stroke, (p=0.012), but little effect on 
cardiovascular death (P=0.73).
In  composite, these randomized trials and meta-analyses indicate that 
benefi ts of  statins are apparent within 4 months after acute coronary 
syndromes manifested, primarily as a reduction in recurrent unstable 
angina. Also, higher intensity statin treatment affords greater benefi t 
than lower intensity treatment in both early and later timeframes after 
acute coronary syndromes.   
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THE SAFETY OF STATINS                                                  
With such successful results garnering in an era of widespread statin 
use and evidence of more benefi cial effects with higher doses, safety 
concerns undoubtedly develop. Cholesterol is a core component of 
cellular membranes and lowering levels intensively could interfere with 
normal regenerative processes. Ophthalmopathy and encephalopathy 
occurred in early studies with dogs on very high doses. However, this 
has not been demonstrated to occur in man.
Statins are remarkably safe and well-tolerated drugs.(15,16) Even at high 
doses the major adverse effects of the statins, namely myopathy and 
raised liver enzymes, are uncommon. The risk of rhabdomyolysis is 
< 4 per 100 000 patient years.
The normal LDL-cholesterol range is 1 – 1.8 mmol/l in healthy neonates, 
hunter-gatherers and free living primates.(17) Randomized clinical trials 
comparing intensive to moderate LDL-cholesterol reduction with statin 
therapy suggest that coronary events are minimized when the LDL-
cholesterol is lowered to below 1.8 mmol/l. However, this still needs to 
be confi rmed in prospective randomized trials.  No major safety issues 
have occurred in studies such as the ARBITER and ASTEROID in which 
LDL-cholesterol levels were reduced to below 1.8 mmol/l with no 
adverse effects.(18)
CONCLUSION                                                                     
Statin therapy for primary and secondary prevention of cardiovascular 
disease has become fi rmly established, and the use of statins in patients 
with, or at high risk for cardiovascular disease represents a major 
advance in pharmacotherapy for the prevention and treatment of 
cardiovascular events. Liberal use of the drugs has made statins arguably 
the most extensively prescribed medications worldwide and relevant 
usage clearly has improved options for these patients. The astute 
clinician needs to be mindful of the rare side effects and individual 
surveillance is mandatory. New evidence suggests that intensive lipid-
lowering with high doses of the more potent statins results in lower 
event rates than moderate lipid lowering and the greatest benefi ts are 
related to the greatest reductions in LDL-cholesterol.(14) However, how 
“low to go” remains unanswered. Although none of the abovementioned 
trials targeted a specifi c level of cholesterol, all of them demonstrated 
signifi cant reduction of LDL-cholesterol levels. Notably, the ASTEROID 
trial demonstrated a signifi cant reduction in atheroma burden on IVUS 
examination after 75% of patients achieved a mean LDL-C level of 
1.8mmol/L during treatment with aggressive rosuvastatin therapy.(18)
Statin therapy should now be considered routine in all patients following 
an acute coronary event. Follow-up testing of LDL cholesterol levels 
should be mandatory to monitor effectiveness of individual drug use 
and assess adherence to therapy and dietary advice. However, in South 
Africa, as in most countries, despite the documented benefi t of early 
intensive statin therapy post an acute coronary event, there appears to 
be a reluctance to prescribe statin therapy, particularly high-dose statin 
therapy.  All physicians should try to adhere to the latest South African 
Lipid guidelines, which have been adopted from the European guidelines 
and should be encouraged to prescribe these remarkable drugs in 
patients at high risk or with documented cardiovascular disease.(19) 
They should strive to achieve the LDL-cholesterol goal of  < 2.5 mmol/
l in all patients with established coronary artery disease. 
Coronary artery disease in the HIV-positive population, particularly 
those receiving highly active anti-retroviral therapy, needs further 
investigation considering our local situation. The dyslipidemic effects of 
anti-retroviral therapy as well as the endothelial dysfunction induced by 
the virus itself are alarming. Further study and monitoring in the South 
African setting is paramount. 
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